This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer	c-Myc (MYC); SUMO1 activating enzyme subunit 1 (SAE1); ubiquitin- like modifier activating enzyme 2 (UBA2; SAE2)	Patient tissue and mouse studies suggest inhibiting SAE1 and/or SAE2 could help treat MYC-driven breast cancers. In mouse xenograft models of MYC-dependent breast cancer, small hairpin RNA against SAE2 decreased tumor growth compared with control shRNA. In breast cancer patients with high MYC levels, those with low tumor levels of SAE1 and SAE2 had longer metastasis-free survival than patients with high tumor levels of SAE1 and SAE2. Next steps could include testing the effects of blocking SAE1 and SAE2 in other MYC-driven cancers.	Patent and licensing status unavailable	Kessler, J.D. <i>et al. Science</i> ; published online Dec. 8, 2011; doi:10.1126/science.1212728 Contact: Thomas F. Westbrook, Baylor College of Medicine, Houston, Texas e-mail: thomasw@bcm.edu Contact: Stephen J. Elledge, Brigham and Women's Hospital, Boston, Mass. e-mail: selledge@genetics.med.harvard.edu
		SciBX 5(1); doi:10.1038/scibx.2012.8 Published online Jan. 5, 2012		